Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

Inclusion Criteria: * Patients older than 18 years of age * Follicular lymphoma, newly diagnosed or previously treated but no more than 2 previous regimens * Relapse of disease must be greater than 6 months after last chemotherapy * Stages II, III or IV * Eastern Cooperative Group (ECOG) performance status of 0 or 1. If ECOG 2-4, poor performance must by due to lymphoma as judged by study investigator. * Patient signed written informed consent * Adequate renal function defined as a glomerular filtration rate (GFR) \> 60 ml/min * Adequate blood counts (absolute neutrophil count ≥ 1,500, platelets ≥100,000), unless low due to lymphomatous involvement of the bone marrow. * No known allergies to the chemotherapeutic agents * No other major disabling co morbidities * Adequate pulmonary function, defined as corrected DLCO greater than 70% of predicted and FEV1 (forced expiratory volume in one second, a test of respiratory function) greater than 50% of predicted. * Adequate hepatic function as assessed by study investigator * Adequate cardiac function, defined as baseline MUGA (Multiple gated acquisition, a test of heart function) \>50% Exclusion Criteria: * Stage I follicular lymphoma * ECOG performance status ≥ 2, unless due to lymphoma * Patient refuses to sign written informed consent * Poor renal function defined as GFR \<60ml/min * Abnormal liver function as assessed by study investigator * Poor bone marrow reserve (absolute neutrophil count \<1,500 and/or platelets \< 100,…